Cookie-Settings

We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

Available now: The complete package for SARS-CoV-2 testing by medac

Click here for the all-inclusive offer

Innovative and fast diagnosis of SARS-CoV-2 via the indirect detection of specific IgM and IgG antibodies from blood


SARS-CoV-2 antibody tests

The serology tests offered by medac for the specific detection of anti-SARS-CoV-2 IgM and IgG antibodies are the first CE IVD-certified tests worldwide. The recombinant, highly specific N and S antigens used guarantee optimal sensitivity even towards neutralising antibodies.

MAGLUMI® 2019nCoV-IgM Antibody Test (CLIA) SARS CoV-2 (S and N antigen)
MAGLUMI® SARS-CoV-2 S-RBD IgG Antibody Test (CLIA) SARS CoV-2 (S-RBD antigen)

 

Methods

The chemiluminescence method supports the high sensitivity and specifity, and allows for a large linear measuring range for the quantification of the IgG antibodies. Furthermore, the IgM test makes use of the µ‑capture system, which has been employed successfully by medac since the 1980s, and which guarantees high sensitivity at the same time as high specifity.

Significance of IgM and IgG detection

Random access device platform

The chemiluminescence imunoassays (CLIA) are handled in a fully automated process and provide initial results after just 35 minutes. Compact table-top devices or larger, stand-alone Maglumi systems by our exclusive partner Snibe are available for automation purposes. Depending on the tests used, up to 280 results an hour can be obtained.

Information on the devices

Portfolio

In addition to the SARS-CoV-2 antibody tests, the portfolio comprises up to 100 other parameters which can be processed at the same time with the Maglumi systems. This includes e.g. inflammation parameters such as CRP, PCT, interleukin-6, or cardiological parameters which also play a role in connection with SARS-CoV-2 diagnostics.

Available tests

Our quality standards

We took as much time as was needed to be able to offer these tests so they meet our quality standards as well as to ensure reliability of supply. The high quality of the tests has meanwhile been confirmed in several independent studies.

More on the studies

Contact our experienced team for a consultation so that we can meet your specific laboratory needs in the best way possible.

The unique technology of the Maglumi® 800 by Snibe by medac ensures exceptionally fast and effective results for your SARS diagnostics.


Watch the Maglumi 800 ® do it.

 

 

Indications

Find out more

Specifications

Find out more